Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4920 N Post Trl TUCSON AZ 85750-7111 |
Tel: | N/A |
Website: | N/A |
IR: | N/A |
Key People | ||
Glen E. Martin President, Chief Executive Officer, Chief Financial Officer, Director | Nicole M. Breen Secretary, Treasurer, Director |
Business Overview |
WEED, Inc. is engaged in the business involving the purchase of land and building commercial grade cultivation centers to consult, assist, manage and lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector. The Company and its subsidiaries are focused on various business opportunities in the cannabis and hemp field, including, but not limited to both indoor and outdoor grows, cultivations and harvest for research, product development, processing and manufacturing of both Pharma and non-Pharma products, services, therapeutics, and treatments on a global basis for both the medical cannabis and hemp global market space. The Company, through its subsidiary, Sangre AT, LLC, doing business as Sangre AgroTech, is engaged in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry. Its other subsidiaries include WEED Israel Cannabis Ltd, WEED Australia Ltd, and others. |
Financial Overview |
For the fiscal year ended 31 December 2023, Weed Inc revenues was not reported. Net loss decreased 98% to $32K. Lower net loss reflects COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH segment loss decrease of 49% to $771K. |
Employees: | 2 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $9.88M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$0.71M as of Dec 31, 2023 |
Net annual income (TTM): | -$0.03M as of Dec 31, 2023 |
Free cash flow (TTM): | -$1.08M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 123,482,685 as of Mar 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |